Analysis of survival differences in advanced triple-negative breast cancer: a real-world study.

Front Oncol · 2025 · PMC12394513 · PMID 40896426

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

It is noteworthy that, except for the premenopausal subgroup, the dnMBC group showed a trend toward lower risks of disease progression and death compared to the rMBC group in all other subgroups.

also in 53,322 other papers

did not reach statistical significanceno p-value reported

The results of the tnAcity trial confirmed that, compared with gemcitabine plus carboplatin or gemcitabine plus albumin-bound paclitaxel, the albumin-bound paclitaxel plus carboplatin regimen could significantly prolong the PFS (5.50 vs 6.00 vs 8.30 months) of patients with aTNBC, and there was also an improving trend in OS (12.1 vs 12.6 vs 16.8 months), although the improvement in OS did not reach statistical significance ( 31 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.